Skip to main content
. 2022 May 3;158(7):301–307. doi: 10.1016/j.medcle.2021.03.036

Table 3.

Patient characteristics according to initial presentation, before and after matching.

All cohort
Demographics & comorbilities Before Matching
After Matching
Tocilizumab (n = 197) Control (n = 347) Standardized difference (%) Tocilizumab (n = 195) Control (n = 347) Standardized difference (%) p Value
Age (mean, years) 61.0 62.7 −12.2 61.0 62.7 −12.0 0.23
Male sex 67.0 60.2 14.1 66.7 64.9 3.7 0.71
Obesity 44.7 31.4 27.5 44.1 44.6 −1.1 0.92
Asthma/COPD 19.3 15.3 10.6 19.0 17.9 2.7 0.78
Cancer/Haematology malignancy 9.6 11.0 −4.3 9.7 9.0 2.5 0.80
Hypertension 42.6 44.7 −4.1 42.5 45.3 −5.7 0.58
Diabetes 21.8 27.1 −12.2 22.1 29.1 16.6 0.12
Transplantation/VIH 8.6 3.2 23.3 8.2 5.9 9.8 0.38
Chronic renal disease 10.2 6.3 13.9 9.2 10.5 −4.7 0.42
SpO2/FiO2 ratio (mean) 209.6 282.5 −77.4 210.4 202.4 8.5 0.67
Early administration cohort
Demographics & comorbilities Tocilizumab (n = 147) Control (n = 347) Standardized difference (%) Tocilizumab (n = 146) Control (n = 347) Standardized difference (%) p Value
Age (mean, years) 60.0 62.7 −19.4 60.1 60.8 −4.7 0.69
Male sex 64.6 60.2 9.1 64.4 63.0 2.8 0.81
Obesity 44.9 31.4 28.0 44.5 37.3 14.9 0.21
Asthma/COPD 17.7 15.3 6.5 17.8 18.5 −1.8 0.88
Cancer/Haematology malignancy 8.2 10.9 −9.5 8.2 8.6 −1.2 0.92
Hypertension 42.9 44.7 −3.6 42.5 45.5 −6.2 0.60
Diabetes 20.4 27.1 −15.7 20.5 21.2 −1.6 0.89
Transplantation/VIH 5.4 3.2 11.2 4.8 5.5 −3.4 0.79
Chronic renal disease 7.5 6.3 4.5 6.8 6.2 2.7 0.81
SpO2/FiO2 ratio (mean) 206.3 282.5 −81.4 206.5 198.4 8.6 0.48

Data are presented as % unless a unit is given (years and ratio).